The partners will focus on new peptide therapeutics for various coronavirus strains. Credit: IRBM.

Merck (MSD) has collaborated with contract research services company IRBM for the identification and development of new peptide therapeutics that can target various strains of coronavirus, including SARS-CoV-2.

The alliance will work on hit to lead optimisation and preclinical development to rapidly advance therapeutic candidates into the clinic.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

IRBM is involved in peptide drug development, including target validation, initial hit identification and the development of a clinical candidate, established in 2010 as a spin-off from MSD.

IRBM CSO Carlo Toniatti said: “With this new outbreak of coronavirus, it makes sense for MSD and IRBM to join forces in this crucial area and work together on a treatment for this devastating pandemic as well as possible future pandemics.

“Our accomplished team here, led by Elisabetta Bianchi, and at MSD have a long heritage in the field of peptide development and have the expertise required to tackle this challenging project.”

As part of the collaboration with Merck, IRBM will leverage its previous SARS research to potentially identify and develop a treatment for SARS-CoV-2 and other future coronavirus strains.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MSD infectious diseases and vaccines discovery vice-president Daria Hazuda noted: “MSD and IRBM have a proud history of conducting breakthrough antiviral research. We look forward to advancing this important programme.”

Merck joined the Covid-19 research and development (R&D) race in May with separate agreements with Themis, IAVI and Ridgeback Biotherapeutics.

Later, in June, Merck collaborated with Japanese biopharmaceutical firm PeptiDream to discover and develop new peptide therapeutics against Covid-19.

Merck and PeptiDream intend to develop therapies with activity against SARS-CoV-2, as well as any future coronavirus outbreaks. The aim is to create drugs targeting several coronavirus strains.